Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors

References

• Krishnakumar R, Kraus WL. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 2010;39:8–24.
   PubMed Web of Science ®Google Scholar
• Jagtap P, Szabo C. Poly(adp-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005;4:421–40.
   PubMed Web of Science ®Google Scholar
• Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171–82.
   PubMed Web of Science ®Google Scholar
• Goldberg MS, Xing D, Ren Y, et al. Nanoparticle-mediated delivery of siRNA targeting parp1 extends survival of mice bearing tumors derived from brca1-deficient ovarian cancer cells. Proc Natl Acad Sci USA 2011;108:745–50.
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(adp-ribose) polymerase. Nature 2005;434:913–7.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Wang PY, Wang YT, et al. An update on poly(adp-ribose)polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy. J Med Chem 2016;59:9575–98.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Olaparib: first global approval. Drugs 2015;75:231–40.
   PubMed Web of Science ®Google Scholar
• Syed YY. Rucaparib: first global approval. Drugs 2017;77:585–92.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Niraparib: first global approval. Drugs 2017;77:1029–34.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Talazoparib: first global approval. Drugs 2018;78:1939–46.
   PubMed Web of Science ®Google Scholar
• Wang L, Yang C, Xie C, et al. Pharmacologic characterization of fluzoparib, a novel poly(adp-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci 2019;110:1064–75.
   PubMed Web of Science ®Google Scholar
• Li N, Bu H, Liu J, et al. An open-label, multicenter, single-arm, phase ii study of fluzoparib in patients with germline brca1/2 mutation and platinum-sensitive recurrent ovarian cancer. Clin Cancer Res 2021;27:2452–8.
   PubMed Web of Science ®Google Scholar
• Wang H, Ren B, Liu Y, et al. Discovery of pamiparib (bgb-290), a potent and selective poly (adp-ribose) polymerase (PARP) inhibitor in clinical development. J Med Chem 2020;63:15541–63.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Guo Y, Liu Y, et al. Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia 2020;22:431–40.
   PubMed Web of Science ®Google Scholar
• Mateo J, Lord CJ, Serra V, Tutt A, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019;30:1437–47.
   PubMed Web of Science ®Google Scholar
• Costa R, Carneiro BA, Wainwright DA, et al. Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Ann Oncol 2017;28:44–56.
   PubMed Web of Science ®Google Scholar
• Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with her2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011;17:4834–43.
   PubMed Web of Science ®Google Scholar
• Olson EM, Abdel-Rasoul M, Maly J, et al. Incidence and risk of central nervous system metastases as site of first recurrence in patients with her2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol 2013;24:1526–33.
   PubMed Web of Science ®Google Scholar
• Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113:2638–45.
   PubMed Web of Science ®Google Scholar
• Campian J, Gutmann DH. CNS tumors in neurofibromatosis. J Clin Oncol 2017;35:2378–85.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–20.
   PubMed Web of Science ®Google Scholar
• Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of brca1-deficient mammary tumors to the PARP inhibitor azd2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008;105:17079–84.
   PubMed Web of Science ®Google Scholar
• Lawlor D, Martin P, Busschots S, et al. PARP inhibitors as p-glyoprotein substrates. J Pharm Sci 2014;103:1913–20.
   PubMed Web of Science ®Google Scholar
• Durmus S, Sparidans RW, van Esch A, et al. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699). Pharm Res 2015;32:37–46.
   PubMed Web of Science ®Google Scholar
• Parrish KE, Cen L, Murray J, et al. Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma xenografts is limited by ineffective drug penetration into the central nervous system. Mol Cancer Ther 2015;14:2735–43.
   PubMed Web of Science ®Google Scholar
• Kizilbash SH, Gupta SK, Chang K, Kawashima R, et al. Restricted delivery of talazoparib across the blood–brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma. Mol Cancer Ther 2017;16:2735–46.
   PubMed Web of Science ®Google Scholar
• Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in cancer. Front Oncol 2013;3:290.
   PubMedGoogle Scholar
• Bai P. Biology of poly(adp-ribose) polymerases: the factotums of cell maintenance. Mol Cell 2015;58:947–58.
   PubMed Web of Science ®Google Scholar
• Martinez-Zamudio RI, Ha HC. PARP1 enhances inflammatory cytokine expression by alteration of promoter chromatin structure in microglia. Brain Behav 2014;4:552–65.
   PubMed Web of Science ®Google Scholar
• Martire S, Mosca L, d'Erme M. PARP-1 involvement in neurodegeneration: a focus on Alzheimer's and Parkinson's diseases. Mech Ageing Dev 2015;146–148:53–64.
   PubMed Web of Science ®Google Scholar
• Pacher P, Szabó C. Role of poly(adp-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: The therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 2007;25:235–60.
   PubMedGoogle Scholar
• Scobie KN, Damez-Werno D, Sun H, et al. Essential role of poly(adp-ribosyl)ation in cocaine action. Proc Natl Acad Sci USA 2014;111:2005–10.
   PubMed Web of Science ®Google Scholar
• Dash S, Balasubramaniam M, Rana T, et al. Poly (adp-ribose) polymerase-1 (PARP-1) induction by cocaine is post-transcriptionally regulated by mir-125b. eNeuro 2017;4:ENEURO.0089-17.2017.
   Web of Science ®Google Scholar
• Reilly SW, Puentes LN, Schmitz A, et al. Synthesis and evaluation of an azd2461[18F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant. Bioorg Chem 2019;83:242–9.
   PubMed Web of Science ®Google Scholar
• Brown JS, O'Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov 2017;7:20–37.
   PubMed Web of Science ®Google Scholar
• Lallo A, Frese KK, Morrow CJ, et al. The combination of the PARP inhibitor Olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. Clin Cancer Res 2018;24:5153–64.
   PubMed Web of Science ®Google Scholar
• Mak JPY, Ma HT, Poon RYC. Synergism between atm and PARP1 inhibition involves DNA damage and abrogating the G2 DNA damage checkpoint. Mol Cancer Ther 2020;19:123–34.
   PubMed Web of Science ®Google Scholar
• Li A, Yi M, Qin S, et al. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol 2019;12:98.
   PubMed Web of Science ®Google Scholar
• Jones P, Wilcoxen K, Rowley M, Toniatti C. Niraparib: a poly(adp-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem 2015;58:3302–14.
   PubMed Web of Science ®Google Scholar
• Zhou J, Ji M, Zhu Z, et al. Discovery of 2-substituted 1h-benzo[d]immidazole-4-carboxamide derivatives as novel poly(adp-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. Eur J Med Chem 2017;132:26–41.
   PubMed Web of Science ®Google Scholar
• Verma R, Bhatia R, Singh G, et al. Design, synthesis and neuropharmacological evaluation of new 2,4-disubstituted-1,5-benzodiazepines as CNS active agents. Bioorg Chem 2020;101:104010.
   PubMed Web of Science ®Google Scholar
• Yu J, Luo L, Hu T, et al. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2. Eur J Med Chem 2022;227:113898.
   PubMed Web of Science ®Google Scholar
• Garberg P, Ball M, Borg N, et al. In vitro models for the blood-brain barrier. Toxicol In Vitro 2005;19:299–334.
   PubMed Web of Science ®Google Scholar
• Mensch J, Oyarzabal J, Mackie C, Augustijns P. In vivo, in vitro and in silico methods for small molecule transfer across the BBB. J Pharma Sci 2009;98:4429–68.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao H, Brewer JT, et al. De novo design, synthesis, and biological evaluation of 3,4-disubstituted pyrrolidine sulfonamides as potent and selective glycine transporter 1 competitive inhibitors. J Med Chem 2018;61:7486–502.
   PubMed Web of Science ®Google Scholar
• Kam TI, Mao X, Park H, et al. Poly(adp-ribose) drives pathologic alpha-synuclein neurodegeneration in Parkinson's disease. Science 2018;362:1–10.
   PubMed Web of Science ®Google Scholar
• Guo Z, Zhang Z, Zhang Y, et al. Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction. Eur J Med Chem 2021;218:113383.
   PubMed Web of Science ®Google Scholar